Ketamine Assisted Psychotherapy – Scholarly Resources

The following is a list of scholarly resources related to ketamine assisted therapy which informs our clinical practice at Spectrum Psychiatric Associates and Spectrum Psychological Associates. Given the novel nature of this treatment, the research is constantly evolving, and this review is not a comprehensive. We update our practice guidelines based on current references available, and we will update this resource list at least every six months.

1. ASPK3 Standards. https://www.askp.org/askp3-standards/
2. Bahji, A., Zarate, C. A., Vazquez, G. H. (2022). *Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. Expert Opin Drug Saf. (06/21/22). 853-866. DOI: 10.1080/14740338.2022.2047928*
3. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 Feb 15;47(4):351-4. doi: 10.1016/s0006-3223(99)00230-9. PMID: 10686270.
4. Blonk MI, Koder BG, Bemt PM, et al. (2010) Use of oral ketamine in chronic pain management: A review. *Eur J Pain* 14: 466–472.
5. Calabrese, Lori. (2019). Ketamine Infusions Stop Suicidal Ideation and Avert Psychiatric Hospitalizations and ER Visits.
6. Chilukuri H, Reddy NP, Pathapati RM, Manu AN, Jollu S, Shaik AB. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J Psychol Med. 2014 Jan;36(1):71-6. doi: 10.4103/0253-7176.127258. Erratum in: Indian J Psychol Med. 2015 Jul-Sep;37(3):379. doi: 10.4103/0253-7176.162911. PMID: 24701015; PMCID: PMC3959024.
7. Domany, Y, Shelton, RC, McCullumsmith, CB. (2020, March) Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial. *Epub*. Retrieved from https://pubmed.ncbi.nlm.nih.gov/31733088/
8. Dore J, Turnipseed B, Dwyer S, Turnipseed A, Andries J, Ascani G, Monnette C, Huidekoper A, Strauss N, Wolfson P. Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. J Psychoactive Drugs. 2019 Apr-Jun;51(2):189-198. doi: 10.1080/02791072.2019.1587556. Epub 2019 Mar 27. PMID: 30917760.
9. Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, Kirkwood K, Aan Het Rot M, Lapidus KA, Wan LB, Iosifescu D, Charney DS. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014 Jun;71(6):681-8. doi: 10.1001/jamapsychiatry.2014.62. PMID: 24740528.
10. Glue P, Loo C, Fam J, Lane HY, Young AH, Surman P; BEDROC study investigators. Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nat Med. 2024 Jul;30(7):2004-2009. doi: 10.1038/s41591-024-03063-x. Epub 2024 Jun 24. PMID: 38914860; PMCID: PMC11271411.
11. Glue P, Medlicott N, Harland S, et al. (2017) Ketamine's dose related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. *J Psychopharmacol* 31: 1302–1305.

12. Glue P, Neehoff SM, Medlicott NJ, Gray A, Kibby G, McNaughton N. Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. J Psychopharmacol. 2018 Jun;32(6):663-667. doi: 10.1177/0269881118762073. Epub 2018 Mar 21. PMID: 29561204.
13. *Greenway, K. T., Garel, N., Jerome, L. & Feduccia, A. (2020). Integrating psychotherapy and psychopharmacology: Psychedelic-assisted psychotherapy and other combined treatments. Expert Review of Clinical Pharmacology.*
14. Heresco-Levy U, Gelfin G, Bloch B, et al. (2013) A randomized add-on trial of high-dose d-cycloserine for treatment resistant depression. *Int J Neuropsychopharmacol* 16: 501–506.
15. Heresco-Levy U, Javitt DC, Gelfin Y, et al. (2006) Controlled trial of d-cycloserine adjuvant therapy for treatment resistant major depres- sive disorder. *J Affect Disord* 93: 239–243.
16. Hull TD, Malgaroli M, Gazzaley A, Akiki TJ, Madan A, Vando L, Arden K, Swain J, Klotz M, Paleos C. At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. J Affect Disord. 2022 Oct 1;314:59-67. doi: 10.1016/j.jad.2022.07.004. Epub 2022 Jul 6. PMID: 35809678.
17. Hyde, Stephen J. (2015). Ketamine for Depression. XLibris.
18. Jha MK, Wilkinson ST, Krishnan K, Collins KA, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Costi S, Malone D, Nikayin S, Nissen SE, Ostroff R, Reti I, Wolski K, Wang D, Hu B, Mathew SJ, Anand A. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 Jun 3;7(6):e2417786. doi: 10.1001/jamanetworkopen.2024.17786. PMID: 38916891; PMCID: PMC11200139.
19. John H. Krystal, Gerard Sanacora, Ronald S. Duman, Rapid-Acting Glutamatergic Antidepressants: The Path to Ketamine and Beyond, Biological Psychiatry,Volume 73, Issue 12, 2013, Pages 1133-1141,ISSN 0006-3223, https://doi.org/10.1016/j.biopsych.2013.03.026. Retrieved from https://www.sciencedirect.com/science/article/pii/S0006322313003363
20. Kheirabadi D, Kheirabadi GR, Mirlohi Z, Tarrahi MJ, Norbaksh A. Comparison of Rapid Antidepressant and Antisuicidal Effects of Intramuscular Ketamine, Oral Ketamine, and Electroconvulsive Therapy in Patients With Major Depressive Disorder: A Pilot Study. J Clin Psychopharmacol. 2020 Nov/Dec;40(6):588-593. doi: 10.1097/JCP.0000000000001289. PMID: 33060432.
21. Kolp, Eli & Friedman, Harris & Krupitsky, Evgeny & Jansen, Karl & Sylvester, Mark & Young, Matthew & Kolp, Anna. (2014). Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications. International Journal of Transpersonal Studies. 33. 84-140. 10.24972/ijts.2014.33.2.84.
22. Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007 Mar;39(1):13-9. doi: 10.1080/02791072.2007.10399860. PMID: 17523581.
23. Luckenbaugh DA, Niciu MJ, Ionescu DF, Nolan NM, Richards EM, Brutsche NE, Guevara S, Zarate CA. Do the dissociative side effects of ketamine mediate its

antidepressant effects? J Affect Disord. 2014 Apr;159:56-61. doi: 10.1016/j.jad.2014.02.017. Epub 2014 Feb 18. PMID: 24679390; PMCID: PMC4065787.
24. *Mathai, D. S., Meyer, M. J., Storch, E. A., & Kosten, T. R. (2020). The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. Journal of Affective Disorders, 264, 123-129. https://doi.org/10.1016/j.jad.2019.12.023*
25. Murrough, J. W., Soleimani, L., DeWilde, K. E., Collins, K. A., Lapidus, K. A., Iacoviello, B. M., et al. (2015). Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol. Med. 45, 3571–3580. doi: 10.1017/S0033291715001506
26. *Oral Extended-Release Ketamine Promising for Treatment-Resistant Depression - Medscape - June 24, 2024.*
27. Rodriguez CI, Kegeles LS, Levinson A, et al. (2013) Randomized con- trolled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept. *Neuropsychopharmacology* 38: 2475–2483.
28. *Ryan, W. C., Marta, C. J., & Koek, R. J. (2014). Ketamine and depression: A review. International Journal of Transpersonal Studies, 33(2), 40–74. DOI: 10.24972/ijts.2014.33.2.40 http://dx.doi.org/10.24972/ijts.2014.33.2.40*
29. *Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., & Nemeroff, C. B. (2017). A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry, 74(4), 399-405. DOI: 10.1001/jamapsychiatry.2017.0080*
30. Sigtermans MJ, van Hilten JJ, Bauer MC, et al. (2009) Ketamine pro- duces effective and long-term pain relief in patients with complex regional pain syndrome type 1. *Pain* 145: 304–311.
31. Szymkowicz SM, Finnegan N and Dale RM (2014) Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder. *J Clin Psychopharmacol* 34: 285–286.
32. Taylor JH, Landeros-Weisenberger A, Coughlin C, Mulqueen J, Johnson JA, Gabriel D, Reed MO, Jakubovski E, Bloch MH. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. Neuropsychopharmacology. 2018 Jan;43(2):325-333. doi: 10.1038/npp.2017.194. Epub 2017 Aug 29. PMID: 28849779; PMCID: PMC5729569.
33. Wilkinson ST, Wright D, Fasula MK, et al. (2017) Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment resistant depression. *Psychother Psychosom* 86: 162– 167.
34. *Wilkinson, S. T., Wright, D., Fasula, M. K., Fenton, L., Griepp, M., Ostroff, R. B., & Sanacora, G. (2017). Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychotherapy and Psychosomatics, 86(3), 162–167. DOI: 10.1159/000457960*
35. Wolfson, P. & Braunstein, M. (2025). Guidelines for the Personal Use and the Clinical Administration of Ketamine Safety and Standard of Care.

https://ketamineresearchfoundation.org/wp-content/uploads/2025/03/KRF-Ketamine-Guidelines.pdf
36. Wolfson, P. & Hartelius, G. (2016). *The Ketamine Papers: Science, Therapy, and Transformation.* Multidisciplinary Association for Psychedelic Studies.
37. Wolfson, P., Cole, R., Lynch, K., Yun, C., Wallach, J., Andries, J., & Whippo, M. (2022). The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of Ketamine and Metabolites. *Journal of Psychoactive Drugs*, *55*(3), 354–358. https://doi.org/10.1080/02791072.2022.2101903
38. Xu Y, Hackett M, Carter G, et al. (2016) Effects of low-dose and very low-dose ketamine among patients with major depression: A systematic review and meta-analysis. *Int J Neuropsychopharmacol* 19: pii: pyv124.
39. Zanicotti CG, Perez D and Glue P (2012) Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. *J Palliat Med* 15: 400–403.
40. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006 Aug;63(8):856-64. doi: 10.1001/archpsyc.63.8.856. PMID: 16894061.